Medical treatments in ambulatory heart failure patients: First data from the BRING-UP-3 Heart Failure Study
Abstract
BACKGROUND
Current ESC guidelines introduced a four-pillar approach for the treatment of HFrEF, and a Class IA recommendation for Empagliflozin and Dapagliflozin in HFmrEF and HFpEF.
OBJECTIVES
BRING-UP-3 Heart Failure (HF) study was designed to guide the Guideline implementation recommendations in HF patients enrolled by a large sample of Italian cardiology sites.
METHODS
BRING-UP-3 HF study is an observational, prospective, nationwide investigation encompassing 179 sites enrolling ambulatory and hospitalized HF patients. The study includes an educational intervention followed by two three-month enrolment periods and by a 6-month follow-up period with end-point evaluation. For HFrEF patients, the objective is to describe the proportion of patients who receive the four pillars. Here we present the baseline data of the ambulatory cohort.
RESULTS
A total of 3,830 ambulatory patients were included in the study. The mean age was 70±12 years (34.5% over 75 years), females were 21.9%. The most prevalent group was HFrEF (58.4%), followed by HFimpEF (17.4%), HFmrEF (14.4%), and HFpEF (9.8%). Hypertension, atrial fibrillation, diabetes mellitus, and chronic kidney disease were reported in 68.2%, 40.4%, 31.0%, and 33.1%, respectively. In HFrEF patients, a high prescription rate (65%) for the four therapeutic pillars was observed; beta-blockers and RASi (mostly ARNIs) were prescribed in over 90% while SGLT2i and MRAs were prescribed in over 80% of cases. In HFmrEF and HFpEF, SGLT2i…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 3,830 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.